<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35004023</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2168-8184</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cureus</Title>
          <ISOAbbreviation>Cureus</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature.</ArticleTitle>
        <Pagination>
          <StartPage>e20203</StartPage>
          <MedlinePgn>e20203</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e20203</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.20203</ELocationID>
        <Abstract>
          <AbstractText>Anti-Yo-associated paraneoplastic cerebellar degeneration (PCD) syndrome is a very rare condition that is most commonly associated with breast and gynecologic cancers. Those cases associated with breast cancer tend to be human epidermal growth factor receptor 2 (HER2)-positive, though the reason for this correlation is unknown. Most commonly, the neurologic symptoms of the PCD syndrome predate the patient's cancer diagnosis. Thus, prompt diagnosis of PCD is essential to allow for early treatment of the neurologic symptoms and the underlying malignancy. However, the prognosis is very poor for the anti-Yo-associated paraneoplastic syndrome, since neurologic damage is usually rapid and irreversible. Further progression may be stopped with appropriate treatment of cancer, but existing neurologic deficits at the time of diagnosis are usually permanent. Steroids, plasma exchange, and rituximab are commonly used treatments, though these have had mixed to poor results.</AbstractText>
          <CopyrightInformation>Copyright © 2021, Chatham et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chatham</LastName>
            <ForeName>Mathew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Brophy College Preparatory, Phoenix, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niravath</LastName>
            <ForeName>Polly</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology/Oncology, Houston Methodist Hospital, Houston, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cureus</MedlineTA>
        <NlmUniqueID>101596737</NlmUniqueID>
        <ISSNLinking>2168-8184</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-yo antibody</Keyword>
        <Keyword MajorTopicYN="N">breast cancer</Keyword>
        <Keyword MajorTopicYN="N">gynecologic cancer</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic neurologic syndrome</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic syndrome</Keyword>
      </KeywordList>
      <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>9</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35004023</ArticleId>
        <ArticleId IdType="pmc">PMC8727331</ArticleId>
        <ArticleId IdType="doi">10.7759/cureus.20203</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Paraneoplastic syndromes: an approach to diagnosis and treatment. Pelosof LC, Gerber DE. Mayo Clin Proc. 2010;85:838–854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paraneoplastic neurological syndromes. Honnorat J, Antoine JC. Orphanet J Rare Dis. 2007;2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868710</ArticleId>
            <ArticleId IdType="pubmed">17480225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Managing paraneoplastic neurological disorders. De Beukelaar JW, Sillevis Smitt PA. Oncologist. 2006;11:292–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16549814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Venkatraman A, Opal P. Ann Clin Transl Neurol. 2016;3:655–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999597</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plasma exchange for treating anti-Yo-associated paraneoplastic cerebellar degeneration: case report and literature review. Hu FQ, Shang FR, Liu JJ, Yuan H. Medicine (Baltimore) 2020;99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7437810</ArticleId>
            <ArticleId IdType="pubmed">32872070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Neurology. 1992;42:1931–1937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. Thöne J, Hohaus A, Lamprecht S, Bickel A, Erbguth F. J Neurol Sci. 2008;272:171–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18632117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van 't Veer M, Smitt PS. J Neurol. 2006;253:16–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. J Neurooncol. 2003;63:187–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12825823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. David YB, Warner E, Levitan M, Sutton DM, Malkin MG, Dalmau JO. https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0142(19961115)78:10%3C2153::AID-CNCR16%3E3.0.CO;2-Y. Cancer. 1996;78:2153–2156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8918408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration. Rojas-Marcos I, Picard G, Chinchón D, et al.  Neuro Oncol. 2012;14:506–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3309857</ArticleId>
            <ArticleId IdType="pubmed">22351748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review. Le May M, Dent S. Curr Oncol. 2018;25:585–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6291278</ArticleId>
            <ArticleId IdType="pubmed">30607127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration. Fu JB, Raj VS, Asher A, Lee J, Guo Y, Konzen BS, Bruera E. Arch Phys Med Rehabil. 2014;95:2496–2499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4252784</ArticleId>
            <ArticleId IdType="pubmed">25051460</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
